Crystallization of the human cannabinoid type 2 receptor

Information

  • Research Project
  • 7052999
  • ApplicationId
    7052999
  • Core Project Number
    R44DA016476
  • Full Project Number
    2R44DA016476-02
  • Serial Number
    16476
  • FOA Number
    PA-02-08
  • Sub Project Id
  • Project Start Date
    8/1/2003 - 20 years ago
  • Project End Date
    8/31/2006 - 17 years ago
  • Program Officer Name
    IKEDA, RICHARD A.
  • Budget Start Date
    1/1/2006 - 18 years ago
  • Budget End Date
    8/31/2006 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    2
  • Suffix
  • Award Notice Date
    12/29/2005 - 18 years ago

Crystallization of the human cannabinoid type 2 receptor

[unreadable] DESCRIPTION (provided by applicant): The cannabinoid type 2 receptor (CB2R) is a target for the treatment of neurophatic pain and several other disorders. Solving the 3-dimensional structure of CB2R would enable the design of better CB2R-selective drugs. Although 30-50% of all current therapeutic drugs on the market modulate the action of different G protein coupled receptors (GPCRs), rhodopsin is the only GPCR for which the crystal structure is known. The bottleneck for GPCR crystallization has been the difficulty to generate large quantities of high-quality receptor sample needed for crystallography. The aim of this project is the crystallization and structural elucidation of CB2R by taking advantage of a novel, proprietary expression system to generate large amounts of homogeneous CB2R. If successful, the CB2R structure would dramatically empower our current cannabinoid receptor drug discovery effort. Moreover, this structure would represent the first non-rhodopsin template for molecular modeling of Family 1 GPCRs. And, in particular, it would be an excellent template for the modeling of the closely related CB1R, involved in many therapeutic areas including drug abuse, immune disorders, and obesity. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R44
  • Administering IC
    DA
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    260006
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
    NIDA:260006\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NOVASITE PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
    113386366
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES